Yan Rolland MD, PhD, Presenter: Consultant, BTG International Ltd

Julien Edeline, Abstract Co-Author: Nothing to Disclose

Eveline Boucher, Abstract Co-Author: Nothing to Disclose

Etienne Garin MD, Abstract Co-Author: Consultant, BTG International Ltd

PVT is a main negative prognostic factor for HCC patients. The goal of this study is to analyse retrospectively patients treated with ThereSphere (T) or sorafenib (S) or both TheraSphere plus sorafenib (T+S).

61 consecutive PVT patients were retrospectively included. Patients treated with sorafenib received a standard dose. Patients treated with TheraSphere were treated using a personalized dosimetric approach. Median progression free survival (PFS) and overall survivals (OS) were estimated with the Kaplan-Meier methos and compared with a log-rank test.

18 patients received T only (30%), 29 S only (48%) and 14 received both T+S (23%). Main PVT was present in 38% of the patients treated by T and 52% for those treated by S only (ns). For patients treated with T the mean lobe dose was 146Gy and 13 patients (40%) received an intensification (mean lobe dose = 197Gy). PFS was 7.7 m (IC 95% : 6.5-8.9) in the group T vs 3.5 (IC 95% : 1.8-5.2) in the group S only (p = 0.026). OS was 23.4 months (IC 95% : 20.6-26.2) in the group T vs 5.1 (IC 95% : 2.3- 7.8) in the group S alone (p<0.001). In the group T, OS was not significantly different if the patients received T alone or both T+S, respectively 24.0months vs 21.5 months (p = 0,96). For patients with a maximum of 3 lesions 0S was still significantly higher for patients treated by T (23.8 months) than for those teated by S only (5.1 months, p<0.001). For patients with unilateral PVT results were still significantly better for T : OS weres 24.0 vs 6.5 months for patients treated respectively with T or S alone (p<0.001).  

In this retrospective study TheraSphere, using a personalized dosimetric approach and intensification, significantly increases OS of PVT patients versus sorafenib.

glass microsphere radioembolization signicficantly increases overal survival for hepatocellular carcinoma with prortal vein thrombosis

Rolland, Y, Edeline, J, Boucher, E, Garin, E, 90Y Loaded Glass Microspheres versus Sorafenib for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Retrospective Study.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14019438.html